Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction clinical trials

Explore recruiting prophylaxis against liver allograft rejection following tolerance induction clinical trials.

Also recruiting in Europe

Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 60 month, single-arm, proof-of-concept study to induce allogeneic tolerance in deceased donor liver transplant recipients using siplizumab, an anti-CD2 antibody in combination with cyclophosphamide and splenectomy.

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction trials by city

Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Toronto Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Vancouver Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Montreal Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Calgary Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Edmonton Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Ottawa Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Winnipeg Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Quebec City Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Hamilton Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Kitchener Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in London Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Halifax Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in New York Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Los Angeles Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Chicago Prophylaxis Against Liver Allograft Rejection Following Tolerance Induction in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease